Publications en collaboration avec des chercheurs de GlaxoSmithKline (United Kingdom) (14)

2024

  1. Triple Therapy and Clinical Control in B+ COPD Patients: A Pragmatic, Prospective, Randomized Trial

    Archivos de Bronconeumologia

2019

  1. Correction: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: A Spanish National Healthcare System perspective (Respiratory Research (2018) 19 (224) DOI: 10.1186/s12931-018-0916-7)

    Respiratory Research

  2. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

    The Lancet, Vol. 393, Núm. 10167, pp. 143-155

2018

  1. Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: A Spanish National Healthcare System perspective

    Respiratory Research, Vol. 19, Núm. 1

  2. Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol in Maintenance-Naïve Patients with Moderate Symptomatic Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis

    Pulmonary Therapy, Vol. 4, Núm. 2, pp. 171-183

2017

  1. Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study

    Advances in Therapy, Vol. 34, Núm. 11, pp. 2518-2533

  2. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study

    The Lancet HIV, Vol. 4, Núm. 12, pp. e536-e546

2016

  1. A study to investigate the efficacy and safety of an anti-interleukin-18 monoclonal antibody in the treatment of type 2 diabetes mellitus

    PLoS ONE, Vol. 11, Núm. 3

2009

  1. Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment

    Antimicrobial Agents and Chemotherapy, Vol. 53, Núm. 12, pp. 5185-5196

2003

  1. Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension

    International Journal of Clinical Practice, Vol. 57, Núm. 4, pp. 273-279

  2. The adjunctive of effect of telmisartan in patients with hypertension uncotrolled on current antihypertensive therapy

    International Journal of Clinical Practice, Vol. 57, Núm. 10, pp. 861-866

2000

  1. Streptococcus pneumoniae in community-acquired respiratory tract infections in Spain: The impact of serotype and geographical, seasonal and clinical factors on its susceptibility to the most commonly prescribed antibiotics

    Journal of Antimicrobial Chemotherapy, Vol. 46, Núm. 4, pp. 557-564

1999

  1. Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: Results of a 1-year (1996-1997) multicenter surveillance study

    Antimicrobial Agents and Chemotherapy, Vol. 43, Núm. 2, pp. 357-359

  2. Antimicrobial resistance of 914 beta-hemolytic streptococci isolated from pharyngeal swabs in Spain: Results of a 1-year (1996-1997) multicenter surveillance study

    Antimicrobial Agents and Chemotherapy, Vol. 43, Núm. 1, pp. 178-180